Akebia Therapeutics (AKBA) Stock Forecast & Price Target

Q: What is AKBA’s average 12-month price target, according to analysts?

Based on analyst ratings, Akebia Therapeutics’s 12-month average price target is 5.67.

Q: What is AKBA’s upside potential, based on the analysts’ average price target?

Akebia Therapeutics has 241.57% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is AKBA a Buy, Sell or Hold?

Akebia Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

Q: What is Akebia Therapeutics’s price target?

The average price target for Akebia Therapeutics is 5.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $6.00 ,the lowest forecast is $5.00. The average price target represents 241.57% Increase from the current price of $1.66.

Q: What do analysts say about Akebia Therapeutics?

Akebia Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

Q: How can I buy shares of AKBA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

1,575 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AKBA Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Akebia

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AKBA Stock 12 Month Forecast

Average Price Target

$5.67

▲(241.57% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $5.67 with a high forecast of $6.00 and a low forecast of $5.00. The average price target represents a 241.57% change from the last price of $1.66.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","1.75":"$1.75","3.5":"$3.5","5.25":"$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.51,1.8553846153846154,2.2007692307692306,2.546153846153846,2.8915384615384614,3.236923076923077,3.582307692307692,3.9276923076923076,4.273076923076923,4.618461538461538,4.963846153846154,5.309230769230769,5.654615384615385,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.51,1.83,2.15,2.4699999999999998,2.79,3.1100000000000003,3.4299999999999997,3.75,4.07,4.39,4.71,5.03,5.35,{"y":5.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.51,1.7784615384615385,2.046923076923077,2.315384615384615,2.583846153846154,2.8523076923076927,3.1207692307692305,3.3892307692307693,3.657692307692308,3.926153846153846,4.194615384615385,4.463076923076923,4.731538461538461,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.69,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$6.00

Average Price Target$5.67

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Julian Harrison

BTIG

Buy

201.20%

Upside

Reiterated

12/02/25

Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), Akebia Therapeutics (NASDAQ: AKBA) and Ionis Pharmaceuticals (NASDAQ: IONS)

Matthew Caufield

H.C. Wainwright

Buy

261.45%

Upside

Reiterated

12/02/25

Strategic Expansion and Market Potential Drive Buy Rating for Akebia TherapeuticsValuation and Risks. We reiterate our Buy rating and $6 price target. Our price target of $6 per share is based on an equally-weighted composite of: (a) $6.84 per share, as a 25x multiple of taxed and diluted 2036 EPS of $1.05 discounted back to and (b) an NPV discounted cash flow between 2025-2036 of $5.81 per share, with a discount rate of 13% and growth rate of 1%. These assumptions are in-line with the expected P/E multiple and discount rates of an early commercial and developmental-stage biopharmaceutical company.

Allison Bratzel

Piper Sandler

Buy

261.45%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: Atricure (NASDAQ: ATRC), Tectonic Therapeutic (NASDAQ: TECX) and Akebia Therapeutics (NASDAQ: AKBA)

Roanna Ruiz

Leerink Partners

Buy

321.69%

Upside

Reiterated

08/22/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Akebia Therapeutics (NASDAQ: AKBA) and Sarepta Therapeutics (NASDAQ: SRPT)

Ed Arce

Westpark Capital

$7.5

Buy

351.81%

Upside

Reiterated

04/04/25

Strategic Developments and Market Opportunities Drive Buy Rating for Akebia Therapeutics

Roger Song

Jefferies

Buy

261.45%

Upside

Initiated

04/01/25

Akebia Therapeutics: Promising Growth Potential with Vafseo Leading the Charge

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Julian Harrison

BTIG

Buy

201.20%

Upside

Reiterated

12/02/25

Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), Akebia Therapeutics (NASDAQ: AKBA) and Ionis Pharmaceuticals (NASDAQ: IONS)

Matthew Caufield

H.C. Wainwright

Buy

261.45%

Upside

Reiterated

12/02/25

Allison Bratzel

Piper Sandler

Buy

261.45%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: Atricure (NASDAQ: ATRC), Tectonic Therapeutic (NASDAQ: TECX) and Akebia Therapeutics (NASDAQ: AKBA)

Roanna Ruiz

Leerink Partners

Buy

321.69%

Upside

Reiterated

08/22/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Akebia Therapeutics (NASDAQ: AKBA) and Sarepta Therapeutics (NASDAQ: SRPT)

Ed Arce

Westpark Capital

$7.5

Buy

351.81%

Upside

Reiterated

04/04/25

Strategic Developments and Market Opportunities Drive Buy Rating for Akebia Therapeutics

Roger Song

Jefferies

Buy

261.45%

Upside

Initiated

04/01/25

Akebia Therapeutics: Promising Growth Potential with Vafseo Leading the Charge

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Akebia Therapeutics

1 Month

xxx

Success Rate

4/9 ratings generated profit

Average Return

+2.23%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 44.44% of your transactions generating a profit, with an average return of +2.23% per trade.

3 Months

xxx

Success Rate

5/9 ratings generated profit

Average Return

+11.50%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +11.50% per trade.

1 Year

Julian HarrisonBTIG

Success Rate

6/9 ratings generated profit

Average Return

+68.00%

reiterated a buy rating 22 days ago

Copying Julian Harrison's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +68.00% per trade.

2 Years

xxx

Success Rate

5/9 ratings generated profit

Average Return

+13.00%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +13.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AKBA Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AKBA has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AKBA average Analyst price target in the past 3 months is 5.67.

Each month's total comprises the sum of three months' worth of ratings.

AKBA Financial Forecast

AKBA Earnings Forecast

Next quarter’s earnings estimate for AKBA is <$0.01 with a range of -$0.05 to $0.03. The previous quarter’s EPS was $0.00. AKBA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AKBA has Performed in-line its overall industry.

AKBA Sales Forecast

Next quarter’s sales forecast for AKBA is $56.17M with a range of $45.40M to $63.86M. The previous quarter’s sales results were $58.77M. AKBA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AKBA has Performed in-line its overall industry.

AKBA Stock Forecast FAQ

What is AKBA’s average 12-month price target, according to analysts?

Based on analyst ratings, Akebia Therapeutics’s 12-month average price target is 5.67.

What is AKBA’s upside potential, based on the analysts’ average price target?

Akebia Therapeutics has 241.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AKBA a Buy, Sell or Hold?

Akebia Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Akebia Therapeutics’s price target?

The average price target for Akebia Therapeutics is 5.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $5.00. The average price target represents 241.57% Increase from the current price of $1.66.

What do analysts say about Akebia Therapeutics?

Akebia Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of AKBA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Akebia Therapeutics (AKBA) Stock Forecast & Price Target

AKBA Analyst Ratings

AKBA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Akebia Therapeutics

AKBA Analyst Recommendation Trends

AKBA Financial Forecast

AKBA Earnings Forecast

AKBA Sales Forecast

AKBA Stock Forecast FAQ

Detailed List of Analyst Forecasts